Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
1(3%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
13
41%
Ph phase_3
2
6%
Ph phase_2
2
6%
Ph phase_1
1
3%
Ph phase_4
7
22%

Phase Distribution

1

Early Stage

2

Mid Stage

9

Late Stage

Phase Distribution25 total trials
Phase 1Safety & dosage
1(4.0%)
Phase 2Efficacy & side effects
2(8.0%)
Phase 3Large-scale testing
2(8.0%)
Phase 4Post-market surveillance
7(28.0%)
N/ANon-phased studies
13(52.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.1%

16 of 17 finished

Non-Completion Rate

5.9%

1 ended early

Currently Active

1

trials recruiting

Total Trials

32

all time

Status Distribution
Active(4)
Completed(16)
Terminated(1)
Other(11)

Detailed Status

Completed16
unknown10
Not yet recruiting3
Withdrawn1
Active, not recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (4.0%)
Phase 22 (8.0%)
Phase 32 (8.0%)
Phase 47 (28.0%)
N/A13 (52.0%)

Trials by Status

not_yet_recruiting39%
withdrawn13%
unknown1031%
active_not_recruiting13%
completed1650%
suspended13%

Recent Activity

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT06541600

Risk Factors for Adverse Outcomes in Sepsis

Completed
NCT06080282

Role of the Kallikrein-kinin System in Septic Cardiomyopathy

Completed
NCT05716256Not Applicable

Effect of Ulinastatin on the Action of NDMRs (Rocuronium / Cisatracurium)

Completed
NCT07672496Not Applicable

Ulinastatin on Systemic Immune-Inflammation in Patients With Complicated Intra-Abdominal Infection

Not Yet Recruiting
NCT07583290

Artificial Intelligence for Ulinastatin Responder Outcome & Risk Assessment in CPB

Active Not Recruiting
NCT03387774Phase 3

Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

Completed
NCT07520370Not Applicable

Effect of Perioperative Ulinastatin on Postoperative Stroke in Patients With Brain Tumor

Not Yet Recruiting
NCT07382375Not Applicable

AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection

Not Yet Recruiting
NCT07090278

Ulinastatin Treatment Reduces the Incidence of Sepsis-associated Encephalopathy

Completed
NCT05534802Not Applicable

Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass

Completed
NCT04711889Not Applicable

Protective Effect of Ulinastatin Against Negative Inflammatory Response and Organ Dysfunction After Acute Type a Aortic Dissection Surgery (PANDA I)

Completed
NCT06268249

Ulinastatin Improves Post-Cardiac Surgery Cognitive Dysfunction

Completed
NCT03089957Not Applicable

Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)

Completed
NCT05895240Phase 4

Role of Ulinastatin in Preventing Severe Sepsis and Consequent Morbidities and Mortality

Unknown
NCT02647554Phase 4

Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China

Completed
NCT05391789Phase 3

Clinical Efficacy of Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response Syndrome

Unknown
NCT04393311Phase 1

Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients

Withdrawn
NCT04990752

Effects of Ulinastatin on Inflammatory Response During ECMO Support

Unknown
NCT04473144Not Applicable

The Effect of Ulistin on Acute Renal Injury in Patients Undergoing OPCAB (Off Pump Coronary Artery Bypass): a Propensity Score Matched Study

Unknown
NCT04028024Not Applicable

Protective Effect in Cardiac Surgery Patients

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
32